MedicinoVa Inc. Files Q3 2024 10-Q Report
Ticker: MNOV · Form: 10-Q · Filed: Nov 13, 2024 · CIK: 1226616
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
MEDCIN Q3 10-Q filed. Financials and ops update for shareholders.
AI Summary
MedicinoVa Inc. reported its third-quarter results for the period ending September 30, 2024. The company's filing details its financial position and operational activities, including information on its equity incentive plans and lease agreements. Specific financial figures and operational metrics are provided within the report.
Why It Matters
This 10-Q filing provides investors and stakeholders with an updated view of MedicinoVa Inc.'s financial health and operational status as of the end of the third quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- Q3 2024 — Reporting Period (The filing covers the third quarter of 2024.)
- 2024-09-30 — Period End Date (The financial information is as of this date.)
- 2024-11-13 — Filing Date (The date the report was submitted to the SEC.)
Key Players & Entities
- MEDICINOVA INC (company) — Filer
- 20240930 (date) — Reporting period end date
- 20241113 (date) — Filing date
- LA JOLLA, CA (location) — Company business and mailing address
- 858-373-1500 (phone_number) — Company business phone
- mnov-20240930.htm (document) — Filed document name
FAQ
What is the company's primary business activity?
MedicinoVa Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where is MedicinoVa Inc. located?
The company's business and mailing address is 4275 Executive Square, Suite 300, La Jolla, CA 92037.
What is the fiscal year end for MedicinoVa Inc.?
The company's fiscal year ends on December 31.
What specific equity incentive plans are mentioned in the filing?
The filing mentions the 'TwoThousandTwentyThreeEquityIncentivePlanMember' and 'TwoThousandThirteenEquityIncentivePlanMember'.
What is the SEC file number for MedicinoVa Inc.?
The SEC file number is 001-33185.
Filing Stats: 4,286 words · 17 min read · ~14 pages · Grade level 17.3 · Accepted 2024-11-13 16:17:03
Key Financial Figures
- $0.001 — ction 12(b) of the Act: Common Stock, $0.001 par value MNOV The Nasdaq Stock Mar
Filing Documents
- mnov-20240930.htm (10-Q) — 981KB
- mnov-ex31_1.htm (EX-31.1) — 13KB
- mnov-ex31_2.htm (EX-31.2) — 14KB
- mnov-ex32_1.htm (EX-32.1) — 10KB
- mnov-ex32_2.htm (EX-32.2) — 10KB
- 0000950170-24-126343.txt ( ) — 4045KB
- mnov-20240930.xsd (EX-101.SCH) — 628KB
- mnov-20240930_htm.xml (XML) — 538KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION 5 ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) 5 ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 17 ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 22 ITEM 4.
CONTROLS AND PROCEDURES
CONTROLS AND PROCEDURES 22
OTHER INFORMATION
PART II. OTHER INFORMATION 23 ITEM 1.
LEGAL PROCEEDINGS
LEGAL PROCEEDINGS 23 ITEM 1A.
RISK FACTORS
RISK FACTORS 23 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 23 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 23 ITEM 4. MINE SAFETY DISCLOSURES 23 ITEM 5. OTHER INFORMATION 23 ITEM 6. EXHIBITS 24
FINANCI AL INFORMATION
PART I. FINANCI AL INFORMATION
CONDENSED CONSOLIDATED F INANCIAL STATEMENTS
ITEM 1. CONDENSED CONSOLIDATED F INANCIAL STATEMENTS. MEDICINOVA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 42,280,618 $ 50,999,442 Prepaid expenses and other current assets 984,860 174,938 Total current assets 43,265,478 51,174,380 Goodwill 9,600,240 9,600,240 In-process research and development 4,800,000 4,800,000 Property and equipment, net 30,813 45,800 Right-of-use asset 403,894 575,406 Other non-current assets 18,996 74,151 Total assets $ 58,119,421 $ 66,269,977 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 708,203 $ 1,003,937 Accrued liabilities and other current liabilities 1,686,739 2,059,238 Operating lease liability 201,976 215,926 Total current liabilities 2,596,918 3,279,101 Deferred tax liability 201,792 201,792 Other non-current liabilities 255,150 410,660 Total liabilities 3,053,860 3,891,553 Commitments and contingencies (Note 4) Stockholders' equity: Common stock, $ 0.001 par value; 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 49,046,246 and 49,046,246 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 49,046 49,046 Additional paid-in capital 479,076,908 478,149,161 Accumulated other comprehensive loss ( 123,803 ) ( 118,090 ) Accumulated deficit ( 423,936,590 ) ( 415,701,693 ) Total stockholders' equity 55,065,561 62,378,424 Total liabilities and stockholders' equity $ 58,119,421 $ 66,269,977 See accompanying notes. 5 MEDICINOVA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Three months ended Nine months ended September 30, September 30, 2024 2023 2024 2023 Revenues $ — $ 1,000,000 $ — $ 1